A resolution designating September 2026 as "National Cholesterol Education Month" and September 30, 2026, as "LDL-C Awareness Day".

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. Res. 914 Agreed to Senate (ATS)]

<DOC>

119th CONGRESS
  2d Session
S. RES. 914

Designating September 2026 as ``National Cholesterol Education Month'' 
          and September 30, 2026, as ``LDL-C Awareness Day''.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                           September 28, 2026

Mrs. Hyde-Smith (for herself, Mr. Peters, Mrs. Britt, and Mr. Padilla) 
 submitted the following resolution; which was considered and agreed to

_______________________________________________________________________

                               RESOLUTION

 
Designating September 2026 as ``National Cholesterol Education Month'' 
          and September 30, 2026, as ``LDL-C Awareness Day''.

Whereas cardiovascular disease is the leading cause of death for men and women 
        in the United States;
Whereas more than 184,000,000 people in the United States are projected to have 
        some type of cardiovascular disease by 2050, and total cardiovascular 
        disease-related costs are projected to triple to $1,800,000,000,000;
Whereas, compared to urban areas, rural areas in the United States have higher 
        death rates for cardiovascular disease and stroke and a 40 percent 
        higher prevalence of cardiovascular disease;
Whereas risk factors contributing to cardiovascular disease and poor health 
        outcomes include elevated low-density lipoprotein cholesterol (referred 
        to in this preamble as ``LDL-C'' ), high levels of lipoprotein(a) 
        cholesterol, hypertension, obesity, low awareness of personal risk 
        factors, genetics, geographic location, and disparities in access to 
        care;
Whereas lipoprotein(a) cholesterol is predominantly genetically inherited and 
        can build up in the walls of blood vessels, creating cholesterol 
        deposits, or plaques, and lead to atherosclerotic cardiovascular 
        disease;
Whereas clinical guidelines recommend that adults in the United States should 
        have a lipoprotein(a) test at least once in their lifetime for 
        cardiovascular risk assessment;
Whereas LDL-C is a modifiable risk factor for cardiovascular disease, and having 
        lower LDL-C is associated with a reduced risk of atherosclerotic 
        cardiovascular disease, including heart attack and stroke, which are the 
        leading causes of cardiovascular-related mortality;
Whereas more than 25.5 percent of adults in the United States have high LDL-C;
Whereas more than 200 studies with more than 2,000,000 patients have broadly 
        established that elevated LDL-C causes atherosclerotic cardiovascular 
        disease;
Whereas atherosclerotic cardiovascular disease is the build-up of cholesterol 
        plaque within the walls of arteries and includes acute coronary 
        syndrome, peripheral arterial disease, and events such as heart attacks 
        and strokes;
Whereas the resources needed to bend the curve on cardiovascular disease exist, 
        yet fewer than 1 in 4 adults with high-risk atherosclerotic 
        cardiovascular disease in the United States achieve guideline-
        recommended LDL-C targets;
Whereas only 33 percent of individuals with atherosclerotic cardiovascular 
        disease who are taking statins, a guideline recommended lipid-lowering 
        therapy, actually achieve LDL-C goals;
Whereas, although clinical guidelines recommend that a patient hospitalized for 
        heart attack receive an LDL-C test in the 90 days following discharge 
        from a hospital, only 27 percent of patients receive the test;
Whereas African-American adults are less likely to receive an LDL-C test in the 
        90 days following discharge from a hospital, despite having a higher 
        prevalence of cardiovascular disease;
Whereas significant gaps in care may lead to subsequent cardiovascular events;
Whereas Federal agencies seek to improve access to and quality of care to reduce 
        heart disease, stroke, and death; and
Whereas September is recognized as National Cholesterol Education Month to raise 
        awareness of cardiovascular disease and the importance of individuals 
        knowing their LDL-C number: Now, therefore, be it
    Resolved, That the Senate--
            (1) encourages all individuals in the United States to know 
        their low density lipoprotein cholesterol (referred to in this 
        resolution as ``LDL-C'') number;
            (2) designates September 2026 as ``National Cholesterol 
        Education Month'';
            (3) designates September 30, 2026, as ``LDL- C Awareness 
        Day''; and
            (4) recognizes the urgent need for screening and treating 
        of elevated LDL-C to reduce the risk of cardiovascular disease 
        and cardiovascular events, including heart attacks and strokes.
                                 <all>